Sign In
Buy ZEAL
$17.59
+0 (+0%)
At Close: Jan 27, 2023
Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results
11:30am, Thursday, 06'th Nov 2025
Press Release – No. 15 / 2025 Zealand Pharma conference call on November 13 at 2pm CET (8am ET) to present third quarter 2025 financial results Copenhagen, Denmark, November 6, 2025 – Zealand P
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
11:05am, Friday, 17'th Oct 2025
Company announcement – No. 22 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations
11:00am, Wednesday, 24'th Sep 2025
Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Copenhagen, Denmark, September 24, 2025 - Zealand Pharma A/S (N
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
04:00pm, Thursday, 11'th Sep 2025
Company announcement – No. 20 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, September 11, 2025 – Zealand Pharma A/S (“Ze
SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025
11:00am, Thursday, 11'th Sep 2025
Press release – No.13 / 2025 SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Copenhagen, Denmark, September 11, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR
Zealand Pharma to participate in upcoming investor conferences in September 2025
11:00am, Thursday, 28'th Aug 2025
Press release – No. 12 / 2025 Zealand Pharma to participate in upcoming investor conferences in September 2025 Copenhagen, Denmark, August 28, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no.
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
04:00pm, Wednesday, 20'th Aug 2025
Company announcement – No. 19 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Zealand Pharma Announces Financial Results for the First Half of 2025
01:00am, Thursday, 14'th Aug 2025
Company announcement – No. 18 / 2025 Zealand Pharma Announces Financial Results for the First Half of 2025 Petrelintide collaboration with Roche off to a strong start, while key leadership appointme
Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results
11:30am, Thursday, 07'th Aug 2025
Press Release – No. 11 / 2025 Zealand Pharma conference call on August 14 at 2pm CET (8am ET) to present second quarter 2025 financial results Copenhagen, Denmark, August 7, 2025 – Zealand Phar
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
12:30pm, Friday, 18'th Jul 2025
Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide
11:29am, Wednesday, 18'th Jun 2025
Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide Body weight reductions of a mean
Zealand Pharma increases its share capital as a result of the exercise of employee warrants
04:00pm, Friday, 06'th Jun 2025
Company announcement – No. 14 / 2025 Zealand Pharma increases its share capital as a result of the exercise of employee warrants Copenhagen, Denmark, June 6, 2025 – Zealand Pharma A/S (“Zealand
Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 �
Company announcement – No. 13 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenh
Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Offic
